Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Biosimilars | Current Treatment | Endocrinology | US/EU | 2017

Login to access report north_east
Contact sales account_box

Recent launches of Merck & Co.’s Lusduna (insulin glargine) in Europe, and Eli Lilly/Boehringer Ingelheim’s Basaglar (insulin glargine) in the United States, have expanded the non-innovator sector of the endocrinology market. Uptake of these products, as well as that of competing insulins and human growth hormone biologics including Omnitrope and Genotropin, will depend on the prescribing behavior of endocrinologists. For this reason, it is critical that manufacturers/marketers of insulin and somatropin biosimilars and brands understand which factors influence endocrinologists’ opinions, actions, and expectations. To this end, Decision Resources Group conducted primary market research with endocrinologists in France, Germany, and the United States.

Questions answered:

  • Have endocrinologists received recommendations to use biosimilars?
  • Are endocrinologists switching patients from reference brands to biosimilars?
  • What factors do endocrinologists consider when choosing among competing biosimilars?
  • How are insulin biosimilars and Omnitrope performing, and what are endocrinologists’ expectations for their future uptake?
  • What are the key drivers and barriers to uptake of insulin and somatropin biosimilars?

Key markets covered:

  • France
  • Germany
  • United States

Key companies mentioned:

  • Boehringer Ingelheim
  • Eli Lilly
  • Merck & Co.
  • Novo Nordisk
  • Sanofi

Key drugs mentioned:

  • Apidra
  • Basaglar/Abasaglar
  • Genotropin
  • Humalog
  • Humatrope
  • Lantus
  • Levemir
  • Lusduna Nexvue/Lusduna
  • Norditropin
  • NovoLog/NovoRapid
  • Nutropin
  • Omnitrope
  • Saizen
  • Toujeo
  • Tresiba
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east